Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

The exploratory study to determine optimum dosing of Axitinib (tyrosine kinase inhibitor) with pharmacokinetic analysis for patients with metastatic renal cell carcinoma

Trial Profile

The exploratory study to determine optimum dosing of Axitinib (tyrosine kinase inhibitor) with pharmacokinetic analysis for patients with metastatic renal cell carcinoma

Status: Not yet recruiting
Phase of Trial: Phase I/II

Latest Information Update: 10 Feb 2018

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Axitinib (Primary)
  • Indications Renal cell carcinoma
  • Focus Adverse reactions; Pharmacogenomic; Pharmacokinetics; Therapeutic Use
  • Most Recent Events

    • 10 Feb 2018 Results (n=44) assessing the relationship between axitinib pharmacogenetics and clinical efficacy/adverse events presented at the 2018 Genitourinary Cancers Symposium
    • 11 Oct 2016 Results presented at the 41st European Society for Medical Oncology Congress
    • 20 Aug 2013 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top